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9* Atypical CFTR variants impact pancreatitis and male infertility in
the North American pancreatitis study
J. LaRusch1, D.C. Whitcomb1. 1University of Pittsburgh, Medicine, Pittsburgh,
United States
CF causing mutations in CFTR have been linked to elevated risk of pancreatitis
without cystic ﬁbrosis. Our recent ﬁndings indicate that a CFTR variant that does
not cause classic CF (R75Q) is yet a risk factor for idiopathic pancreatitis. Our
study assesses the impact of both CF and atypical CFTR mutations on severity and
onset of idiopathic pancreatitis.
45 CFTR variants were tested among 956 chronic and recurrent acute pancreatitis
patients and 467 unrelated controls. Detailed questionnaires were completed by
subjects and physicians on pancreatic and CF-like symptoms.
Twelve CF causing CFTR mutations and seven CFTR variants of uncertain clinical
signiﬁcance were identiﬁed more frequently in patients than controls. While the
common CF causing mutation F508del composed 30% of all CFTR variants
identiﬁed among patients, the seven atypical CFTR variants composed 60%. The
ages of onset for both acute and chronic pancreatitis were signiﬁcantly lower
among CFTR variant carriers than patients with no identiﬁed variants. There was
no signiﬁcant difference in the ages of onset between patients carrying a classic
CF mutation or a variant of uncertain clinical signiﬁcance. Male infertility was
signiﬁcantly more common among patients with a compound atypical genotype, as
compared to those with no identiﬁed variants (p = 0.00003), but not among either
CF or atypical mutation carriers.
In addition to classic CF causing mutations, this new class of atypical CFTR variants
may play a major role in the etiopathology of pancreatitis. Compound heterozygosity
with atypical CFTR variants is a signiﬁcant risk factor for both pancreatitis and
male infertility.
10 Cystic ﬁbrosis genotype in northern Portugal
T.D.F. Barbosa1, C. Ferraz2, A. Amorim3, L. Guedes Vaz2,4, V. Senra1,
H. Rocha5. 1Hospital Maria Pia/Centro Hospitalar Porto, Pediatrics, Porto,
Portugal; 2Hospital de S. Joa˜o, Pediatrics, Porto, Portugal; 3Hospital de S. Joa˜o,
Pulmonology, Porto, Portugal; 4Faculdade de Medicina do Porto, Porto, Portugal;
5Hospital de criancas Maria Pia, Immunoallergology, Porto, Portugal
Background: Genotype characterization of Cystic Fibrosis (CF) population in
northern Portugal. Demographic registry was analyzed from the two reference
centers treating pediatric and adult patients in that speciﬁc region (Hospital Maria
Pia/Centro Hospitalar do Porto and Hospital S. Joa˜o Porto).
Methods: Clinical data of CF patients were reviewed and analyzed according to
demographic indicators, such as geographic family origin, age, sex and CFTR
genotype.
Results: 105 patients were obtained, 53 (50.5%) females and 52 (49.5%) males,
with a median age of 14.3 years (minimum 0.79, maximum 52.1 years; std
deviation 10). Most CF patients (85, 81%) had p.Phe508del genotype, 56 (53.3%)
of which were homozygous. 20 (19%) patients had other mutations, such as R334W,
present in 9 (8.6%) and A561E, present in 8 (7.6%) of CF patients.
Conclusions: Genotype characterization is essential to improve our knowledge
about CF. In northern Portugal, the most common mutation in CFTR is the F508del,
followed by R334W and A561E. The A561E is found with some frequency in
Northern Portugal, compared with other mutations.
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As it was previously established c.2184insA (c.2052_2053insA) is the second most
common CF mutation in patients from Western Ukraine, accounting more than
7.5% of mutated CFTR alleles. After inclusion of the c.2184insA mutation in the
testing panel this allele was identiﬁed among 25 CF patients. Two patients were
homozygous for this mutation. In 18 CF patients p.F508del was detected in trans
and Slavic mutation CFTRdele2,3(21kB), p.R334W, c.3849+10kbC>T, c.2143del
were detected once in the second allele.
14/25 patients with the c.2184insA mutation were diagnosed with CF during the
ﬁrst year of life (no neonatal CF screening in Ukraine), two cases presented with
meconium ileus. All patients have a high level of Cl concentration in sweat. Three
patients were pancreatic sufﬁcient (p.R334W, c.3849+10kbC>T, p.F508del in trans)
and for 18 measured cases Fecal elastase-1 was found to be very low (17.7±8.3 ug/g
of stool). One patient homozygous for this mutation died at age of 7.
Patients with the c.2184insA mutation have higher occurrence of CF liver disease
and infections prevalence despite no signiﬁcant differences in their average age,
age distribution and glucose intolerance compare with patients without c2184insA
mutation.
The c.2184insA mutation is associated with early and severe manifestations of CF,
similar to those of patients with other genotypes except with respect to bacterial
colonization of the bronchopulmonary tree. These observed differences could be
the subject of investigation in future studies addressing the molecular defect of
CFTR protein expressed from c.2184insA mutant alleles in bronchus and lung and
developing mutation depending CF treatment.
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Objectives: To establish a novel prevalence score for meconium ileus (MIP score) as
a predictor of the severity of CFTR mutations.
Methods: A large cohort representing approximately 70% of the Canadian CF pop-
ulation was sampled for ongoing modiﬁer studies in CF. Data acquisition included
meconium ileus (MI) and genotype. Meconium ileus prevalence scores (MIP) were
calculated for the most frequent mutations as the ratio between CF patients with MI
and all CF patients (MI and no MI) and compared with pancreatic phenotype. Initial
analysis focuses on patients carrying dF508 on one allele allowing each mutation on
the second allele to be assigned a MIP score.
Results: The analysis included 2117 of 2504 recruited CF patients with 2 identiﬁed
CFTR mutations and dF508 on one allele. The overall prevalence of MI was 16%.
Table 1 demonstrates the wide range of MIP scores (0.2 to 0.08) between subjects with
“pancreatic insufﬁcient” genotypes.
Table 1
MIP CFTR mutation Patient # with MI; no MI Pancreas phenotype
0.29 711+1G>T 11: 27 PI
0.28 G542X 20; 52 PI
0.19 dF508 239; 1024 PI
0.10 N1303K 4; 35 PI
0.08 G551D 4; 49 PI
0.04 G85E 1; 23 PI/PS
0.00 A455E 0; 40 PI/PS
0.00 L206W, 3849+10kbC>T, P67L,
R117H, 2789+5G>A, IVS8−5T
0; 95 PS
Conclusion: Prevalence scores of well deﬁned phenotypes are only possible using
large and well characterized CF populations. The derived scoring system may more
accurately predict the genotype/phenotype correlations of CFTR mutations and be
useful for patient stratiﬁcation in modiﬁer gene studies.
